- Home
- GIGM vs INDP Comparison
GIGM vs INDP Comparison
Compare GIGM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- INDP
- Stock Information
- Founded
- GIGM 1998
- INDP 2000
- Country
- GIGM Taiwan
- INDP United States
- Employees
- GIGM N/A
- INDP N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- INDP Health Care
- Exchange
- GIGM Nasdaq
- INDP Nasdaq
- Market Cap
- GIGM 17.9M
- INDP 6.0M
- IPO Year
- GIGM 2000
- INDP N/A
- Fundamental
- Price
- GIGM $1.48
- INDP $11.11
- Analyst Decision
- GIGM
- INDP Strong Buy
- Analyst Count
- GIGM 0
- INDP 2
- Target Price
- GIGM N/A
- INDP $8.50
- AVG Volume (30 Days)
- GIGM 17.4K
- INDP 692.4K
- Earning Date
- GIGM 07-30-2025
- INDP 08-11-2025
- Dividend Yield
- GIGM N/A
- INDP N/A
- EPS Growth
- GIGM N/A
- INDP N/A
- EPS
- GIGM N/A
- INDP N/A
- Revenue
- GIGM $3,103,000.00
- INDP N/A
- Revenue This Year
- GIGM N/A
- INDP N/A
- Revenue Next Year
- GIGM N/A
- INDP N/A
- P/E Ratio
- GIGM N/A
- INDP N/A
- Revenue Growth
- GIGM N/A
- INDP N/A
- 52 Week Low
- GIGM $1.26
- INDP $7.56
- 52 Week High
- GIGM $1.80
- INDP $66.64
- Technical
- Relative Strength Index (RSI)
- GIGM 54.63
- INDP 51.26
- Support Level
- GIGM $1.41
- INDP $9.45
- Resistance Level
- GIGM $1.52
- INDP $11.71
- Average True Range (ATR)
- GIGM 0.04
- INDP 2.10
- MACD
- GIGM 0.01
- INDP 0.16
- Stochastic Oscillator
- GIGM 74.36
- INDP 28.75
About GIGM GigaMedia Limited
GigaMedia Ltd is a publisher of online games. It has only one reportable segment, Digital Entertainment service. Digital Entertainment service business operates a portfolio of online games, mainly targeting online game players across Europe, and Asia, including Greater China and Southeast Asia. The company's portfolio of online games includes predominantly PC-based, non-cash gambling, or casino casual games, including MahJong and various card and table games. The company's product lines include MahJong, AkaSeka, Yume 100, Fun Vegas, and others. The company operates in Taiwan and Hong Kong.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.